Subscribe to RSS
DOI: 10.1055/s-0029-1225283
© Georg Thieme Verlag KG Stuttgart · New York
Pneumologie 2009
Diseases of the lung and air passages 2009Publication History
Publication Date:
10 June 2009 (online)

Was ist neu?
-
Asthma bronchiale: Mit der „multiple hit”-Hypothese bekommt die bisherige Sicht zur Pathophysiologie einen anderen Fokus. Neue Medikamente zielen auf a) die zielgerichtete Hemmung von Entzündungsmediatoren und b) die Entwicklung weiterer inhalativer Kombinationspräparate. FeNO trägt nur unwesentlich zu einer besseren Therapiesteuerung bei.
-
Chronisch obstruktive Lungenerkrankung: Tiotropiumbromid verbesserte in der UPLIFT-Studie wichtige klinische COPD-Erfolgsparameter. Accelerometer ermöglichen die Aktivität von Patienten auch zu Hause verlässlich zu erfassen. 2009 werden Indacaterol als erstes 24h-wirksames inhalatives b2-Mimetikum und zudem ein Phosphodiesterase-4-Inhibitor Marktreife erlangen. 2008 wurden neue Leitlinien zur Begutachtung der Silikose und zur Langzeitsauerstofftherapie veröffentlicht.
-
Lungenkarzinom: Es wurde die TNM-Klassifizierung überarbeitet.
-
Pneumonie: Die Mortalität beträgt < 2% und die Krankenhausmortalität 5-20%.
-
Lungentransplantation: Die bilaterale Lungentransplantation ist wegen der längeren Überlebenszeit der Einzellungentransplantation überlegen.
-
Idiopathische Lungenfibrose: Diverse antiinflammatorische und antifibrotisch wirkende Medikamente befinden sich in der klinischen Prüfung.
-
Ambulante Beatmungsmedizin: Publikation einer Stellungnahme zur Heimbeatmungstherapie von COPD-Patienten. Das oSAS ist mittlerweile auch zu einem Risikofaktor für Kinder geworden.
Literatur
- 1
Adcock I M, Caramori G, Chung K F.
New targets for drug development
in asthma.
Lancet.
2008;
372
1073-1087
Reference Ris Wihthout Link
- 2
Alkhalil M, Schulman E, Getsy J.
Obstructive sleep apneasyndromeand asthma: what are the links?.
J Clin Sleep Med.
2009;
5
71-78
Reference Ris Wihthout Link
- 3
Anderson G P.
Endotyping asthma: new insights into key pathogenic mechanisms
in a complex, heterogenous disease.
Lancet.
2008;
372
1107-1119
Reference Ris Wihthout Link
- 4
Antoniou K M, Nicholson A G, Dimadi M. et al .
Long-term clinical effects of interferon gamma-1ß and
colchicine in idiopathic pulmonary fibrosis.
Eur Respir
J.
2006;
28
496-504
Reference Ris Wihthout Link
- 5
Antoniu S A.
Targeting the endothelin pathway in the idiopathic pulmonary
fibrosis: the role of bosentan.
Expert Opin Ther Targets.
2008;
12
1077-1084
Reference Ris Wihthout Link
- 6
Azuma A, Nukiwa T, Tsuboi E. et
al .
Double-blind, placebo-controlled trial of pirfenidone
in patients with idiopathic pulmonary fibrosis.
Am J Respir
Crit Care Med.
2005;
171
1040-1047
Reference Ris Wihthout Link
- 7
Bateman E D, Hurd S S, Barnes P J. et al .
Global strategy for asthma
management and prevention: GINA executive summary.
Eur
Respir J.
2008;
31
143-178
Reference Ris Wihthout Link
- 8
Baur X, Heger M, Köhler D. et al .
Diagnostik und Begutachtung der Berufskrankheit
Nr 4101 Quarzstaublungenerkrankung (Silikose).
Pneumologie.
2008;
62
659-684
Reference Ris Wihthout Link
- 9
Beeh K M, Derom E, Kanniess F, Cameron R B, Higgins M W, van As A.
Indacaterol,
a novel inhaled ß2-agonist, provides sustained 24-h bronchodilation
in asthma.
Eur Respir J.
2007;
29
871-878
Reference Ris Wihthout Link
- 10
Bhattacharjee R, Kheirandish-Gozal L, Pillar G, Gozal D.
Cardiovacular complications
of obstructive sleep apnea syndrome: evidence from children.
Prog
Cardiovasc Dis.
2009;
51
416-433
Reference Ris Wihthout Link
- 11
Bradshaw T A, Matusiewicz S P, Crompton G K, Innes J A, Greening A P.
Intravenous
magnesium sulphate provides no additive benefit to standard management
in acute asthma.
Respir Med.
2008;
102
142-149
Reference Ris Wihthout Link
- 12
Chanez P, Burge S, Dahl J, Creemers J, Lamarca R, Garcia
Gil E.
Once-daily administration of aclidinium
bromide, a novel, long-acting anticholinergic: a phase II, dose-finding
study (abst.).
Am J Respir Crit Care Med.
2008;
177
A349
Reference Ris Wihthout Link
- 13
Chiba Y, Arima J, Sakai H, Misawa M.
Lovastatin inhibits bronchial hyperresponsiveness
by reducingRhoA signaling in rat allergic asthma.
Am J
Physiol Lung Cell Mol Physiol.
2008;
294
L705-L713
Reference Ris Wihthout Link
- 14
Christie J D, Edwards L B, Aurora P. et al .
Registry of the International Society for Heart
and Lung Transplantation: twenty-fifth official adult lung and heart/lung transplantation
report – 2008.
J Heart Lung Transplant.
2008;
27
957-969
Reference Ris Wihthout Link
- 15
Cohen J, Douma W R, ten H acken
NH, Vonk J M, Oudkerk M, Postma D S.
Ciclesonide
improves measures of small airway involvement in asthma.
Eur
Respir J.
2008;
31
1213-1220
Reference Ris Wihthout Link
- 16
Demedts M, Behr J, Buhl R. et
al .
High-dose acetylcysteine in idiopathic pulmonary
fibrosis.
N Engl J Med.
2005;
353
2229-2242
Reference Ris Wihthout Link
- 17
Denning D W, O’Driscoll B R, Powell G. et al .
Randomized controlled trial
of oral antifungal treatment for severe asthma with fungal sensitization.
The fungal asthma sensitization trial (FAST) study.
Am
J Respir Crit Care Med.
2008;
179
11-18
Reference Ris Wihthout Link
- 18
Fabbri L M, Luppi F, Beghe B, Rabe K F.
Complex chronic comorbidities
of COPD.
Eur Respir J.
2008;
31
212
Reference Ris Wihthout Link
- 19
Gillissen A, Wirtz H, Hoheisel G B.
Paradigmenwechsel in der Therapieempfehlung des Asthma bronchiale.
Med Klinik.
2007;
102
399-403
Reference Ris Wihthout Link
- 20
Gontijo-Amaral C, Ribeiro M A, Gontijo L S, Condino-Neto A, Ribeiro J D.
Oral magnesium supplementation
in asthmatic children: a double-blind randomized placebo-controlled
trial.
Eur J Clin Nutr.
2007;
61
54-60
Reference Ris Wihthout Link
- 21
Groome P A, Bolejack V, Crowley J J. et al .
The IASLC Lung Cancer Staging Project:
validation of the proposals for the revision of the T, N, and M
descriptors and consequent stage groupings in the forthcoming (seventh)
edeition of the TNM classification of malignant tumors.
J
Thorac Oncol.
2007;
2
603-612
Reference Ris Wihthout Link
- 22
Haldar P, Brightling C E, Hargadon B. et al .
Mepolizumab and exacerbations of refractory
eosinophilic asthma.
N Engl J Med.
2009;
360
973-984
Reference Ris Wihthout Link
- 23
Holt P G, Sly P D.
Prevention of
allergic respiratory disease in infants: current aspects and future
perspectives.
Curr Opin Allerg Clin Immunol.
2007;
7
547-555
Reference Ris Wihthout Link
- 24
Hothersall E J, Chaudhuri R, McSharry C. et al .
Effects of atorvastatin added to inhaled corticosteroid
on lung function and sputum cell counts in atopic asthma.
Thorax.
2008;
63
1070-1075
Reference Ris Wihthout Link
- 25
King jr T E, Behr J, Brown K K. et al .
BUILD-1: a randomized placebo-controlled
trial of bosentan in idiopathic pulmonary fibrosis.
Am
J Respir Crit Care Med.
2008;
177
75-81
Reference Ris Wihthout Link
- 26
Magnussen H, Kirsten A -M, Köhler D, Morr H, Sitter H, Worth H.
Leitlinien zur Langzeit-Sauerstofftherapie
der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin
e. V.
Pneumologie.
2008;
62
748-746
Reference Ris Wihthout Link
- 27
Make B J, Kanniess F, Bateman E D, Linberg S E.
Efficacy of
3 different doses of carmoterol, a long-acting beta2-agonist in
patients with COPD (abst.).
Am J Respir Crit Care Med.
2008;
177
A961
Reference Ris Wihthout Link
- 28
Mannino D M, Thorn D, Swensen A, Holguin F.
Prevalence and outcomes
of diabetes, hypertension and cardiovascular disease in COPD.
Eur Respir J.
2008;
32
962-969
Reference Ris Wihthout Link
- 29
Mohammed S, Goodacre S.
Intravenous and nebulised
magnesium sulphate for acute asthma: systematic review and meta-analysis.
Emerg Med J.
2007;
24
823-830
Reference Ris Wihthout Link
- 30
Nair P, Pizzichini M M, Kiarsgaard M. et al .
Mepolizumab for prednisone-dependent asthma
with sputum eosinophilia.
N Engl J Med.
2009;
360
985-993
Reference Ris Wihthout Link
- 31
Pacanowski M A, Amsden G W.
Interferon gamma-1ß in
the treatment of idiopathic pulmonary fibrosis.
Ann Pharmacother.
2005;
39
1678-1686
Reference Ris Wihthout Link
- 32
Rabe K F, Bateman E D, O’Donnell D E, Witte S, Bredenbröker D, Betsuyaku T.
Roflumilast – an
oral anti-inflammatory treatment for chronic obstructive pulmonary
disease: a randomised controlled trial.
Lancet.
2005;
366
563-571
Reference Ris Wihthout Link
- 33
Raghu G, Brown K K, Costabel U. et al .
A randomized placebo controlled trial assessing the
efficacy and safety of etanercept in patients with idiopathic pulmonary
fibrosis (IPF).
Am J Respir Crit Care Med.
2008;
178
948-955
Reference Ris Wihthout Link
- 34
Randerath W, Lorenz J, Windisch W. et al .
Betreuung von Patienten mit maschineller Beatmung
unter häuslichen und heimpflegerischen Bedingungen.
Pneumologie.
2008;
62
305-308
Reference Ris Wihthout Link
- 35
Shaw D E, Berry M A, Thomas M. et al .
The use of exhaled nitric oxide to guide
asthma management.
Am J Respir Crit Care Med.
2007;
176
231-237
Reference Ris Wihthout Link
- 36
Singh S, Loke Y K, Furberg C D.
Inhaled anticholingergics and risk of major
adverse cardiovascular events in patients with chronic obstructive
pulmonary disease.
JAMA.
2008;
100
1439-1450
Reference Ris Wihthout Link
- 37
Smith A D, Cowan J O, Brasset K P, Herbison G P, Taylor D R.
Use of exhaled nitric oxide measurements
to guide treatment in chronic asthma.
N Engl J Med.
2005;
352
2163-2173
Reference Ris Wihthout Link
- 38
Tashkin D P, Celli B R, Senn S. et al .
A 4-year trial of tiotropium in chronic
obstructive pulmonary disease.
N Engl J Med.
2008;
359
1543-1554
Reference Ris Wihthout Link
- 39
Tzortzaki E G, Antoniou K M, Zervou M I. et al .
Effects of antifibrotic
agents on TGF-beta1, CTGF and IFN-gamma expression in patients with
idioapathic pulmonary fibrosis.
Respir Med.
2007;
101
1821-1829
Reference Ris Wihthout Link
- 40
Watz H, Waschki B, Meyer T, Magnussen H.
Physical activity in patients
with COPD.
Eur Respir J.
2009;
33
362-272
Reference Ris Wihthout Link
- 41
Welte T, Köhnlein T.
Global and local
epidemiology of community-acquired pneumonia: the experince of the
CAPNETZ Network.
Semin Respir Crit Care Med.
2009;
30
127-135
Reference Ris Wihthout Link
- 42
Wenzel S E, Wilbraham D, Fuller R, Burmeister E, Longphre M.
Effect of in interleukin-4 variant on late phase asthmatic response to
allergen challenge in asthmatic patients:results of two phase 2a
studies.
Lancet.
2007;
370
1422-1431
Reference Ris Wihthout Link
- 43
Wu P, Dupont W D, Griffin M R. et al .
Evidence of a causal role of winter virus
infection during infancy in early childhood asthma.
Am
J Respir Crit Care Med.
2008;
178
1123-1129
Reference Ris Wihthout Link
Prof. Dr. A. Gillissen
Robert-Koch-Klinik, Thoraxzentrum des Klinikums
St. Georg
Nikolai-Rumjanzew-Str. 100
04207 Leipzig
Phone: 0341/4231-202
Fax: 0341/4231-203
URL: http://www.rkk-leipzig.de